Vor Biopharma Inc. (VOR)
| Market Cap | 917.91M +910.9% |
| Revenue (ttm) | n/a |
| Net Income | -695.98M |
| EPS | -70.50 |
| Shares Out | 54.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,173,332 |
| Open | 15.98 |
| Previous Close | 16.08 |
| Day's Range | 15.91 - 17.32 |
| 52-Week Range | 2.62 - 65.80 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 45.33 (+167.59%) |
| Earnings Date | May 11, 2026 |
About VOR
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for VOR stock is "Buy." The 12-month stock price target is $45.33, which is an increase of 167.59% from the latest price.
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Comp...
Vor Bio files to sell 5.34M shares of common stock for holders
16:13 EDT Vor Bio (VOR) files to sell 5.34M shares of common stock for holders
Vor Bio price target lowered to $31 from $32 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $31 from $32 and keeps a Buy rating on the shares. The firm says the company has “undergone
Vor Bio price target raised to $15 from $9 at Wedbush
Wedbush raised the firm’s price target on Vor Bio (VOR) to $15 from $9 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and
Vor Bio price target lowered to $40 from $55 at Stifel
Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy rating on the shares. The global Phase 3 UPSTREAM MG trial evaluating
Vor Bio price target lowered to $40 from $55 at Stifel
Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy rating on the shares. The global Phase 3 UPSTREAM MG trial evaluating
Vor Bio doses first patient in UPSTREAM SjD study
Vor Bio (VOR) announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active prim...
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease
First and only dual BAFF/APRIL inhibitor in primary Sjögren's disease, one of the largest autoimmune diseases without an approved therapy First and only dual BAFF/APRIL inhibitor in primary Sjögren's ...
Vor Bio initiated with a Buy at Jefferies
Jefferies analyst Farzin Haque initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target which represents 268% upside. The company pivoted to autoimmune diseases in June
Vor Bio to sell 5.338M shares at $14.05 in private placement
Vor Bio (VOR) announced that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a
Vor Bio Announces $75 Million Private Placement with TCGX
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a s...
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and o...
Vor Bio initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Vor Bio (VOR) with an Overweight rating and $30 price target The firm believes the company’s telitacicept is “derisked” in two indications that represent $5B
Vor Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
Telitacicept, a BAFF/APRIL inhibitor, is advancing in global phase III trials for myasthenia gravis and Sjögren's disease, showing best-in-disease efficacy and a strong safety profile. The company is well-funded through 2028 and targets multi-billion dollar markets in both indications.
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting an...
Vor Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
A strategic pivot to autoimmune diseases is underway, with telitacicept as the lead asset showing strong efficacy and safety in large patient populations. Global Phase 3 trials in myasthenia gravis and Sjögren's are advancing, supported by a $450M cash runway and a seasoned leadership team.
Vor Bio initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target The firm believes the company is positioned to launch telitacicept to indications
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting an...
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announce...
Vor Bio price target lowered to $46 from $64 at Baird
Baird lowered the firm’s price target on Vor Bio (VOR) to $46 from $64 and keeps an Outperform rating on the shares. The firm updated its model. Published first on
Vor Bio price target lowered to $40 from $43 at JPMorgan
JPMorgan analyst Anupam Rama lowered the firm’s price target on Vor Bio (VOR) to $40 from $43 and keeps an Overweight rating on the shares. The firm updated models in
Vor Bio initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Vor Bio (VOR) with a Buy rating and no price target The firm cites telitacicept’s “promising” mechanism of action, “differentiated strong data,” and potential across
Vor Bio prices 13.88M shares at $10.81 in private placement
Vor Bio (VOR) entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional
Vor Bio Announces $150 Million Private Placement
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a se...